case_images: PMC10499621_01
case_images: The tumor progression of the patient before and after treatment. (A, B) Representative lesions in the lung lobes according to computed tomography images at various points. (C) Magnetic resonance images at various points. The tumor is indicated by red arrows. ICI, immune checkpoint inhibitor; IMRT: intensity-modulated radiotherapy; PD, progressive disease; PR, partial response.
case_images: fphar-14-1257592-g001.jpg
case_images: PMC10499621_01_fphar-14-1257592-g001.jpg
case_images: F1
case_images: HRCT scan revealed a significant reduction in the size of nodules in the RUL of the lung (measuring 1.8 cm x 0.8 cm) compared to the baseline (Figure 1A). However, a head MRI showed an increase in the number and size of brain metastases compared to the baseline (Figure 1C). Subsequent MRI scans demonstrated effective control of the brain metastases (Figure 1C). Follow-up chest HRCT and brain MRI scans conducted after aumolertinib treatment revealed a significant reduction in the size of the lung mass in the RUL (Figure 1A) and complete disappearance of the lesions in the occipital lobe (Figure 1C). The tumour continued growing aggressively in the bilateral lung lobes (Figure 1B).
case_images: Identification of L833V and H835L in EGFR exon 21 by next-generation sequencing.
case_images: fphar-14-1257592-g002.jpg
case_images: PMC10499621_01_fphar-14-1257592-g002.jpg
case_images: F2
case_images: This comprehensive analysis identified the presence of synchronous mutations, p.L833V and p.H835L, in exon 21 of the EGFR gene (Figure 2).
case_images: Case timeline. PFS, progression-free survival. IMRT: intensity-modulated radiotherapy; PD, progressive disease; PR, partial response.
case_images: fphar-14-1257592-g003.jpg
case_images: PMC10499621_01_fphar-14-1257592-g003.jpg
case_images: F3
case_images: The OS duration for the patient was 29.0 months (Figure 3).